Venus Remedies Share Price Today | Stock Price & Venus Remedies Share Screener
As of September 30, 2026, the live Venus Remedies share price (NSE: VENUSREM) is ₹1,796.10 on NSE and ₹1,751.75 on BSE, up 5.00% from the previous close, with shares trading between ₹1,730.00 and ₹1,796.10 in today's trading session, and a 52-week range of ₹434.35–₹1,796.10. Check VENUSREM 52-week high low for the annual price range and momentum. Use the Venus Remedies stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Venus Remedies opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹264 and net income of ₹48, with EBITDA of ₹68, an operating margin of 24.0% and a profit margin of 18.2%.
Venus Remedies Share Price Chart
Track the current stock price of Venus Remedies with an interactive chart. Analyse VENUSREM share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Venus Remedies stock quote in one place.
The quote of ₹1,796.10 sits between the 52-week low of ₹434.35 and the 52-week high of ₹1,796.10, and the latest session moved 5.00% from the previous close.
Venus Remedies Company Profile - Fundamental Screener
Screen Venus Remedies company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for VENUSREM shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE411B01019.
Company Details
Classification
Identifiers and Leadership
Venus Remedies Balance Sheet Screener
Screen VENUSREM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹854, up from ₹716 in 2025.
Latest statistics put total assets at ₹854 and shareholder funds at ₹664, with a leverage ratio of 0.01.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 854 | 716 | 627 | 601 | 580 | 556 | 644 | 733 | 751 | 765 |
| Current Assets | 395 | 397 | 360 | 323 | 278 | 234 | 294 | 265 | 260 | 259 |
| Fixed Assets | 232 | 229 | 219 | 216 | 241 | 262 | 289 | 364 | 389 | 406 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 28 | 19 | 60 | 58 | 47 | 58 | 96 | 137 | 159 | 180 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 664 | 561 | 488 | 460 | 440 | 400 | 323 | 333 | 362 | 389 |
| Share Capital | 13 | 13 | 13 | 13 | 13 | 12 | 12 | 12 | 12 | 12 |
| Reserves & Surplus | 650 | 548 | 474 | 447 | 427 | 374 | 311 | 320 | 350 | 376 |
Venus Remedies Income Statement Screener - Profit & Revenue Analysis
Screen Venus Remedies income statement and profit fundamentals. Analyze VENUSREM quarterly results. Venus Remedies reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Mar, revenue was ₹264 and net profit was ₹48, equal to earnings per unit of ₹35.53, at an operating margin of 24%.
In that period expenses were ₹196, interest cost ₹0 and tax ₹14. The next period listed, 2026-Jun, shows revenue of ₹182 and net profit of ₹23.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 264 | 182 | 202 | 141 | 195 | 183 | 199 | 110 | 178 | 189 | 159 | 97 | 171 | 146 | 145 |
| Expenses | 196 | 145 | 166 | 122 | 162 | 143 | 176 | 97 | 163 | 159 | 131 | 85 | 150 | 131 | 137 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 68 | 37 | 36 | 19 | 33 | 40 | 23 | 13 | 16 | 30 | 28 | 13 | 21 | 14 | 8 |
| Operating Profit % | 24.00% | 19.00% | 15.00% | 11.00% | 16.00% | 21.00% | 10.00% | 10.00% | 4.00% | 10.00% | 16.00% | 11.00% | 11.00% | 8.00% | 4.00% |
| Depreciation | 7 | 7 | 5 | 6 | 6 | 7 | 6 | 6 | 6 | 5 | 8 | 8 | 6 | 7 | 8 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 62 | 30 | 31 | 13 | 27 | 34 | 18 | 7 | 9 | 25 | 20 | 5 | 14 | 8 | 0 |
| Tax | 14 | 7 | 10 | 3 | 6 | 8 | 7 | 6 | 6 | 5 | 9 | 4 | 4 | 1 | 0 |
| Net Profit | 48 | 23 | 21 | 10 | 20 | 26 | 11 | 1 | 4 | 20 | 11 | 1 | 10 | 7 | 0 |
| EPS | 35.53 | 17.18 | 15.71 | 7.18 | 15.06 | 19.14 | 7.86 | 0.92 | 2.63 | 14.66 | 8.27 | 0.88 | 7.44 | 5.13 | 0.17 |
Venus Remedies Cash Flow Screener - Liquidity Fundamentals
Screen VENUSREM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹156, and net cash flow was an outflow of ₹32.
Over the same period, investing activities used ₹185 and financing activities used ₹3.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 156 | 86 | 37 | 37 | 41 | 132 | 78 | 45 | 31 | 59 |
| Investing Activities | -185 | -77 | -9 | -58 | -17 | 57 | -5 | -11 | 9 | -18 |
Financing and Net Cash | ||||||||||
| Financing Activities | -3 | -1 | -1 | -1 | -10 | -162 | -73 | -35 | -39 | -44 |
| Net Cash Flow | -32 | 9 | 28 | -22 | 14 | 27 | 0 | -1 | 0 | -4 |
Venus Remedies Shareholding Pattern Screener
See Venus Remedies shareholding pattern with promoter, FII, and DII holdings. Check Venus Remedies promoter holding and ownership changes for VENUSREM on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 41.76%, foreign institutions 2.80%, domestic institutions 1.20% and the public 44.39%, spread across 18,403 shareholders.
The shareholder count was 18,403 in 2026-Mar, compared with 21,905 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% |
Institutional Investors | ||||||||
| FII Holding | 2.80% | 2.92% | 1.34% | 2.24% | 1.86% | 2.26% | 1.48% | 1.06% |
| DII Holding | 1.20% | 0.89% | 0.00% | 0.11% | 0.75% | 1.03% | 0.15% | 0.15% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 44.39% | 44.31% | 46.81% | 47.70% | 45.30% | 45.16% | 46.89% | 46.25% |
| Other Holding | 9.85% | 10.12% | 10.09% | 8.19% | 10.33% | 9.80% | 9.73% | 10.78% |
| Shareholder Count | 18,403 | 21,905 | 19,982 | 19,307 | 17,725 | 18,606 | 19,913 | 19,614 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Venus Remedies. Venus Remedies dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹10.00 per unit for 2026-March, a yield of 0.56%, compared with ₹0.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹10.00, ₹0.00 and ₹0.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹10.00 | 0.56% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Venus Remedies Stock Index Membership - Nifty & Sensex
See which indices include Venus Remedies stock. Check VENUSREM index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Venus Remedies Market Events Screener - Corporate Actions
Get Venus Remedies corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Venus Remedies stock events that may affect VENUSREM share price, along with derivatives, futures and options activity and sector gainers.
12 corporate actions are listed, the most recent entry being Annual General Meeting dated August 20, 2026, with a record date of August 20, 2026.
It is followed by Dividend dated August 7, 2026 and Quarterly Result Announcement dated July 20, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-20 | 2026-08-20 | Annual General Meeting | NA | 56.05% |
| 2026-08-07 | 2026-08-07 | Dividend | ₹ 10.00 /share | 37.52% |
| 2026-07-20 | 2026-07-20 | Quarterly Result Announcement | NA | 6.02% |
| 2026-05-26 | 2026-05-26 | Quarterly Result Announcement | NA | 20.91% |
| 2026-01-29 | 2026-01-29 | Quarterly Result Announcement | NA | -3.15% |
| 2025-11-10 | 2025-11-10 | Quarterly Result Announcement | NA | 1.78% |
| 2025-08-22 | 2025-08-22 | Annual General Meeting | NA | 14.50% |
| 2025-08-01 | 2025-08-01 | Quarterly Result Announcement | NA | -2.92% |
| 2025-05-26 | 2025-05-26 | Quarterly Result Announcement | NA | 3.36% |
| 2025-02-04 | 2025-02-04 | Quarterly Result Announcement | NA | -1.96% |
| 2024-10-29 | 2024-10-29 | Quarterly Result Announcement | NA | -0.66% |
| 2024-09-23 | 2024-09-23 | Annual General Meeting | NA | 0.93% |
Venus Remedies Competitors Screener - Peer Stocks Comparison
Screen VENUSREM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 429,001 | 35.84 | 61,674 | 12.69% | 11,565 | 36.68 |
| Divis Laboratories | 242,798 | 84.36 | 11,067 | 13.95% | 2,568 | 51.70 |
| Torrent Pharmaceuticals | 179,633 | 84.01 | 13,886 | 20.34% | 2,138 | 41.12 |
| Zydus Life Science | 113,057 | 24.88 | 27,658 | 17.64% | 5,026 | 47.64 |
| Cipla | 106,831 | 32.42 | 29,045 | 2.24% | 3,870 | 34.78 |
| Laurus Labs | 106,274 | 98.56 | 6,868 | 22.01% | 890 | 58.70 |
| Mankind Pharma | 104,129 | 50.48 | 14,636 | 14.85% | 1,938 | 61.75 |
| Dr Reddys Laboratories | 99,945 | 31.47 | 35,059 | 3.90% | 4,158 | 53.84 |
| Aurobindo Pharma | 96,289 | 25.97 | 34,145 | 5.56% | 3,503 | 50.30 |
| Lupin | 91,449 | 16.71 | 29,039 | 26.75% | 5,356 | 31.59 |
Venus Remedies Company Announcements - News & Reports Screener
Screen VENUSREM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 1, 2026.
The next most recent announcements are dated September 26, 2026 and September 10, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-01 | Intimation For Change In Company Identification Number (CIN). | - |
| 2026-09-26 | Closure of Trading Window | - |
| 2026-09-10 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-09 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-08 | Social Media Post On Shareholders Awareness On Transfer Of Physical Shares. | - |
| 2026-08-21 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-08-21 | Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association | - |
| 2026-08-21 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-08-20 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-08-20 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-08-04 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-27 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-24 | Reg. 34 (1) Annual Report. | - |
| 2026-07-24 | Reg. 34 (1) Annual Report. | - |
| 2026-07-24 | Notice Of 37Th Annual General Meeting Of The Company. | - |
| 2026-07-22 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-20 | Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association | - |
| 2026-07-20 | Unaudited Financial Results As On 30Th June 2026. | - |
| 2026-07-20 | Board Meeting Outcome for Outcome Of Board Meeting. | - |
| 2026-07-18 | Social Media Post On KYC Updation | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹1,796.10, within a 52-week range of ₹434.35 to ₹1,796.10. The P/E ratio is 20.53 and the P/B ratio is 3.59, with earnings per unit of ₹76.90. Market capitalisation stands at ₹2,317.84 Cr and the dividend yield is 0.56%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 5, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.